Altre lingue Statera Biopharma, Inc. Nasdaq

Azioni

STAB

US8575611046

Mercato chiuso - Nasdaq Altri mercati azionari 15:30:01 20/05/2024			Variaz. 5gg	Var. 1 gen.
0,0007 ^USD	0,00%		0,00%	-99,98%

2022	Statera Biopharma, Inc. riporta i risultati degli utili per il terzo trimestre e i nove mesi conclusi il 30 settembre 2022	CI
2022	Statera Biopharma, Inc. riporta i risultati degli utili per il secondo trimestre e i sei mesi conclusi il 30 giugno 2022	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs.	15/03/23
STATERA BIOPHARMA, INC. : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	01/02/23
STATERA BIOPHARMA, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits (form 8-K)	20/01/23
Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index	17/01/23
Statera Biopharma, Inc.(OTCPK:STAB) dropped from NASDAQ Composite Index	11/01/23
STATERA BIOPHARMA, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	15/11/22
STATERA BIOPHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	14/11/22
Statera Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22
Statera Biopharma : Material Agreement - Form 8-K	07/11/22
STATERA BIOPHARMA, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	07/11/22
Statera Biopharma, Inc. announced that it has received $0.4 million in funding from Silverback Capital Corporation	07/11/22
Statera Biopharma, Inc. announced that it expects to receive $0.765 million in funding	01/11/22
STATERA BIOPHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	28/10/22
Statera Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	28/10/22
STATERA BIOPHARMA, INC. : Other Events (form 8-K)	27/10/22
STATERA BIOPHARMA, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	24/10/22
STATERA BIOPHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	21/10/22
Statera Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	21/10/22
US Futures Lower Amid Earnings Reports, Ahead of Flash PMI Data	21/10/22
Top Premarket Gainers	21/10/22

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Statera Biopharma, Inc. Nasdaq

Azioni

STAB

US8575611046

Altre lingue

Filtri